Regorafenib + Panitumumab for Colorectal Cancers
Evaluate the safety of regorafenib and panitumumab
KRAS and NRAS Wild-type Colorectal Cancer
DRUG: regorafenib + panitumumab
Safety of regorafenib + panitumumab, safety of combination for duration of treatment, Safety of the drug combination will be measured by number and severity of adverse events experienced while patients are on treatment which will be about 2-3 months if not more depending on the response to treatment.
Evaluate the safety of regorafenib and panitumumab